GM-CSF may also upregulate CCL17 expression in macrophages, thereby mediating inflammatory arthritis and associated inflammatory pain (Achuthan et al, 2016) and CCL17 levels were also significantly reduced following anti-GM-CSF therapy in RA patients (Guo et al, 2019). Here, CCL17 is linked to rheumatoid arthritis.